| Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective C Hernando, B Ortega-Morillo, M Tapia, S Moragón, MT Martínez, ... International journal of molecular sciences 22 (15), 7812, 2021 | 82 | 2021 |
| The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene E Tormo, A Adam-Artigues, S Ballester, B Pineda, S Zazo, ... Scientific reports 7 (1), 41309, 2017 | 80 | 2017 |
| The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors E Tormo, S Ballester, A Adam-Artigues, O Burgués, E Alonso, B Bermejo, ... Scientific reports 9 (1), 5316, 2019 | 70 | 2019 |
| Regulation of the yeast Hxt6 hexose transporter by the Rod1 α-arrestin, the Snf1 protein kinase, and the Bmh2 14-3-3 protein V Llopis-Torregrosa, A Ferri-Blázquez, A Adam-Artigues, E Deffontaines, ... Journal of Biological Chemistry 291 (29), 14973-14985, 2016 | 49 | 2016 |
| Circulating mir-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer I Garrido-Cano, V Constâncio, A Adam-Artigues, A Lameirinhas, S Simón, ... International Journal of Molecular Sciences 21 (19), 7427, 2020 | 32 | 2020 |
| Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer A Adam-Artigues, EJ Arenas, A Martínez-Sabadell, F Brasó-Maristany, ... Science advances 8 (20), eabk2746, 2022 | 31 | 2022 |
| Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer A Adam-Artigues, I Garrido-Cano, S Simón, B Ortega, S Moragón, ... ESMO open 6 (1), 100039, 2021 | 26 | 2021 |
| MicroRNAs as a clue to overcome breast cancer treatment resistance I Garrido-Cano, B Pattanayak, A Adam-Artigues, A Lameirinhas, ... Cancer and Metastasis Reviews, 1-29, 2022 | 17 | 2022 |
| Identification of a two-microRNA signature in plasma as a novel biomarker for very early diagnosis of breast cancer A Adam-Artigues, I Garrido-Cano, JA Carbonell-Asins, A Lameirinhas, ... Cancers 13 (11), 2848, 2021 | 17 | 2021 |
| MicroRNA-33b suppresses epithelial–mesenchymal transition repressing the MYC–EZH2 pathway in HER2+ breast carcinoma B Pattanayak, I Garrido-Cano, A Adam-Artigues, E Tormo, B Pineda, ... Frontiers in oncology 10, 1661, 2020 | 13 | 2020 |
| miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies I Garrido‐Cano, A Adam‐Artigues, A Lameirinhas, JF Blandez, ... Cancer Communications 42 (12), 1412, 2022 | 10 | 2022 |
| miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer P Cabello, S Torres-Ruiz, A Adam-Artigues, J Forés-Martos, MT Martínez, ... Cancers 15 (7), 2138, 2023 | 8 | 2023 |
| Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy I Garrido-Cano, A Adam-Artigues, A Lameirinhas, JF Blandez, ... ACS Applied Materials & Interfaces 15 (32), 38323-38334, 2023 | 6 | 2023 |
| A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells V Calvo, W Zheng, A Adam-Artigues, KA Staschke, X Huang, JF Cheung, ... Clinical Cancer Research 29 (24), 5155-5172, 2023 | 3 | 2023 |
| AXL-a new player in resistance to HER2 blockade A Adam-Artigues, EJ Arenas, J Arribas, A Prat, JM Cejalvo Cancer Treatment Reviews, 102639, 2023 | 3 | 2023 |
| miR-503-5p induces doxorubicin resistance in triple-negative breast cancer. I Garrido-Cano, A Adam-Artigues, A Lameirinhas, B Pattanayak, E Tormo, ... Journal of Clinical Oncology 39 (15_suppl), 1083-1083, 2021 | 1 | 2021 |
| The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach A Adam-Artigues, E Tormo, F Rojo, JA Perez-Fidalgo, S Zazo, ... Annals of Oncology 30, v110, 2019 | 1 | 2019 |
| Immune evasion by dormant disseminated cancer cells: A Fermi paradox? A Adam-Artigues, LEV Salazar, JA Aguirre-Ghiso Cancer Cell 42 (1), 13-15, 2024 | | 2024 |
| Delivery of miR-200c-3p using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy. ACS Appl Mater Interfaces I Garrido Cano, A Adam Artigues, A Lameirinhas, JF Blandez Barradas, ... American Chemical Society (ACS), 2023 | | 2023 |
| Hereditary Risk Assessment for BRCA Breast and/or Ovarian Cancer MT Martínez, M Tapia, L Candia, B Bermejo, I Garrido-Cano, ... Journal of Cancer Science and Clinical Therapeutics 6 (3), 251-261, 2022 | | 2022 |
